| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/06/2013 | CN102908337A Microencapsulated amino-acid composition and preparation method of microencapsulated amino-acid composition |
| 02/06/2013 | CN102908336A Stable preparation of phosphatidylserine and preparation method, application as well as application product of stable preparation |
| 02/06/2013 | CN102908335A Rosuvastatain calcium composition and preparation method thereof |
| 02/06/2013 | CN102908334A Oxygen-contained capsule |
| 02/06/2013 | CN102908333A Atorvastatin calcium self-nano-emulsified soft capsule and preparation method thereof |
| 02/06/2013 | CN102908325A Sevelamer carbonate medical tablet composition and preparation method thereof |
| 02/06/2013 | CN102908319A Vitamin C sustained-release pellets and method for preparing same |
| 02/06/2013 | CN102907606A Beta-glucan composition and application thereof |
| 02/06/2013 | CN102603627B Naphthlamide derivative used as protein kinase inhibitor and histone deacetylase inhibitor and preparation method of naphthlamide derivative |
| 02/06/2013 | CN102295684B Insulin chain A human leukocyte antigen (HLA)-A*0201 restrictive cytotoxic T lymphocyte (CTL) epitope altered peptide ligand and application thereof |
| 02/06/2013 | CN102247372B Methionine-containing medicinal composition and preparation method thereof |
| 02/06/2013 | CN102210717B Compositions comprising Lactobacillus plantarum strains in combination with tannin and new Lactobacillus plantarum strains |
| 02/06/2013 | CN102146074B Preparation method of pyrrole derivative and application thereof |
| 02/06/2013 | CN102133231B Product prepared by shark cartilage for supplementing calcium and promoting metabolism and development of cartilage and preparation method thereof |
| 02/06/2013 | CN101632832B Component for reducing body fat formation and application thereof |
| 02/06/2013 | CN101490028B C-phenyl glycitol compound |
| 02/06/2013 | CN101365338B Herbal powder extracts and methods of preparing and using the same |
| 02/06/2013 | CN101336689B Caiguosu food and production method thereof |
| 02/05/2013 | US8367848 Process for the preparation of amorphous calcium salt of atorvastatin |
| 02/05/2013 | US8367664 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors |
| 02/05/2013 | US8367608 Method for promoting secretion of glucagon-like peptide-1 by administering κ-casein |
| 02/05/2013 | US8367607 Oxyntomodulin peptide analogue |
| 02/05/2013 | US8367072 Composition for treating obesity and method of using the same |
| 02/05/2013 | CA2557766C Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 02/05/2013 | CA2557320C Fused heterocyclic derivatives for prevention or treatment of hyperglycemia |
| 02/05/2013 | CA2519250C Therapeutic agent for diabetes mellitus |
| 02/05/2013 | CA2501719C Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 02/05/2013 | CA2479555C Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients |
| 02/05/2013 | CA2464277C Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| 02/05/2013 | CA2428176C Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 01/31/2013 | WO2013016742A1 Composition for obesity treatment |
| 01/31/2013 | WO2013016741A1 Dietary supplement for use in a weight loss program |
| 01/31/2013 | WO2013016544A2 Templated islet cells and small islet cell clusters for diabetes treatment |
| 01/31/2013 | WO2013016501A1 Formulations of thiophene compounds |
| 01/31/2013 | WO2013016278A2 Modulators of antiviral signaling pathways and therapeutic uses thereof |
| 01/31/2013 | WO2013015535A2 Novel pyrimidine derivative and pharmaceutical composition including same as an active ingredient |
| 01/31/2013 | WO2013015288A1 Lipase activity inhibitor |
| 01/31/2013 | WO2013014569A1 Quinolinyl glucagon receptor modulators |
| 01/31/2013 | WO2013013614A1 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof |
| 01/31/2013 | WO2013013609A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| 01/31/2013 | WO2013013505A1 9-aminomethyl substituted tetracycline compound |
| 01/31/2013 | WO2013013500A1 Radix puerariae and semen litchi drink for reducing blood glucose and preparation method thereof |
| 01/31/2013 | WO2013013417A1 Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds |
| 01/31/2013 | WO2013013273A1 Modulators of protease activated receptors |
| 01/31/2013 | WO2012170899A3 Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases |
| 01/31/2013 | WO2012143416A3 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives |
| 01/31/2013 | US20130030180 Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators |
| 01/31/2013 | US20130030053 Novel niddm regimen |
| 01/31/2013 | US20130030033 4-trimethylammonio-butyrates as cpt2 inhibitors |
| 01/31/2013 | US20130030029 Glucagon Antagonists |
| 01/31/2013 | US20130030024 Method of Administering Pirfenidone Therapy |
| 01/31/2013 | US20130030020 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| 01/31/2013 | US20130030019 Novel prolylcarboxypeptidase inhibitors |
| 01/31/2013 | US20130030014 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
| 01/31/2013 | US20130030007 Obesity Small Molecules |
| 01/31/2013 | US20130030000 Pharmaceutical compositions for the treatment of pain and other indications |
| 01/31/2013 | US20130029996 Special composition for the use thereof as a drug |
| 01/31/2013 | US20130029995 Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands |
| 01/31/2013 | US20130029987 Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| 01/31/2013 | US20130029968 Indazoles |
| 01/31/2013 | US20130029966 Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| 01/31/2013 | US20130029963 1,2,4-triazine-4-amine derivatives |
| 01/31/2013 | US20130029962 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands |
| 01/31/2013 | US20130029958 Synthetic bile acid compositions and methods |
| 01/31/2013 | US20130029939 Novel glucokinase activators and methods of using same |
| 01/31/2013 | US20130029938 Chemical Compounds |
| 01/31/2013 | US20130029935 Mineral amino acid polysaccharide complex |
| 01/31/2013 | US20130029906 Method of regulating ppar, obesity related pathways and their associated metabolic impact |
| 01/31/2013 | US20130029905 Formulation containing curcuminoids exhibiting enhanced bioavailability |
| 01/31/2013 | US20130028997 Compositions, Products, Therapeutic Uses and Procedures for the Production and/or Crystallization of Extracts of Encelia Canescens LAM (Coronilla De Fraile) |
| 01/31/2013 | US20130028991 Dietary supplement for use in a weight loss program |
| 01/31/2013 | US20130028988 Composition for obesity treatment |
| 01/31/2013 | US20130028987 Method of treating psoriasis |
| 01/31/2013 | US20130028974 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 01/31/2013 | US20130028969 Method for stable and controlled delivery of (-)-hydroxycitric acid |
| 01/31/2013 | US20130028955 Sustained release oral matrix and methods of making thereof |
| 01/31/2013 | US20130028923 Kdr peptides and vaccines comprising the same |
| 01/31/2013 | US20130028921 Composition comprising coumestrol or a bean extract containing coumestrol |
| 01/31/2013 | US20130028918 Insulin conjugate using an immunoglobulin fragment |
| 01/31/2013 | US20130028916 Antagonist anti-il-7 receptor antibodies and methods |
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028881 Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
| 01/31/2013 | US20130028874 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| 01/31/2013 | US20130028870 Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease |
| 01/31/2013 | US20130028869 Feed supplement comprising oligosaccharides and medium chain fatty acids |
| 01/31/2013 | US20130028849 Agent For Stimulating The Expression of Loxl |
| 01/31/2013 | CA2842838A1 9-aminomethyl substituted tetracycline compounds |
| 01/31/2013 | CA2842730A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| 01/31/2013 | CA2841237A1 Quinolinyl glucagon receptor modulators |
| 01/31/2013 | CA2816207A1 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis |
| 01/30/2013 | EP2551255A1 Cannabinoid quinone derivatives |
| 01/30/2013 | EP2550972A1 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases |
| 01/30/2013 | EP2550968A1 Non-surgical removal of localized fat accumulation with a bile salt in conjunction with an analgesic or anti-inflammatory agent |
| 01/30/2013 | EP2550254A1 Cyclopentyl - and cycloheptylpyrazoles as fxr modulators |
| 01/30/2013 | EP2550063A1 Alr2 inhibitors and their synthesis from a natural source |
| 01/30/2013 | EP2550011A1 Use of pcsk9 as a vaccine for lowering cholesterol |
| 01/30/2013 | EP2550004A1 Heparan sulfate replacement therapy |
| 01/30/2013 | EP2549998A1 Pharmaceutical composition comprising a pyrimidineone derivative |
| 01/30/2013 | EP2549996A1 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amin0-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
| 01/30/2013 | CN102906159A Amine polymers for use as bile acid sequestrants |